Q4 2023 Neurotech International Ltd Activities Report Call Transcript
Thank you for standing by, and welcome to the Neurotech International quarterly investor conference call. (Operator Instructions) I would now like to hand the conference over to Dr. Thomas Duthy. Please go ahead.
Thank you, Zach, and good morning, everyone. Thank you for joining me on the third Neurotech International quarterly conference call. My pleasure to present to you today a summary of the company's financial performance and operating activities for the three months ended June 30, 2023, being our Q4 FY23.
I trust that all of you on today's call have had a chance to read the announcement as lodged with ASX this morning. I'd now like to provide an overview of the quarterly activities and our outlook for the remainder of the 2023 calendar year.
Firstly, I'd like to highlight the continued safety results collected following our Phase I/II clinical trial of NTI164 in autism spectrum disorder or ASD. On May 31, the company announced it has obtained clearance from Human
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)